The presence of CA19-9 in serum and saliva from Lewis blood-group negative cancer patients

Jpn J Cancer Res. 1988 Apr;79(4):538-43. doi: 10.1111/j.1349-7006.1988.tb01624.x.

Abstract

Eighteen cancer patients showed high levels of CA19-9 in sera, even though the blood-group phenotypes of their red blood cells were Le(a-b-). Seven of these patients (group I) were determined as Le(a-b-) from both red blood cells and saliva consistently, whereas eleven other patients (group II) secreted either Le(a) or Le(b) antigen in saliva and showed the expression of incompatible Lewis blood-group antigens. GDP-fucose: N-acetyl-glucosaminide alpha(1----4)-L-fucosyltransferase was demonstrated to be present in salivas from both group I and group II. These results suggest that a cancer-associated alteration of Lewis blood-group antigen expression occurs in cancer patients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antigens, Neoplasm / analysis*
  • Antigens, Tumor-Associated, Carbohydrate
  • Blood Grouping and Crossmatching
  • Enzyme Precursors / blood
  • Female
  • Fucosyltransferases / blood
  • Guanosine Diphosphate Fucose
  • Humans
  • Lewis Blood Group Antigens*
  • Male
  • Neoplasms / blood*
  • Neoplasms / enzymology
  • Neoplasms / immunology
  • Phenotype
  • Saliva / enzymology
  • Saliva / immunology*

Substances

  • Antigens, Neoplasm
  • Antigens, Tumor-Associated, Carbohydrate
  • Enzyme Precursors
  • Lewis Blood Group Antigens
  • Guanosine Diphosphate Fucose
  • Fucosyltransferases
  • 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase